002198.SZ
Guangdong Jiaying Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 3.32
−1.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 385.0M | 383.8M | 376.2M | 533.2M | 659.2M |
| Cost of Revenue | 179.9M | 153.7M | 150.7M | 185.5M | 228.5M |
| Gross Profit | 205.2M | 230.0M | 225.4M | 347.7M | 430.7M |
| Operating Expenses | |||||
| R&D Expense | 10.5M | 9.0M | 6.8M | 10.1M | 15.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 26.7M | 33.1M | 48.5M | 48.1M | 43.7M |
| Selling & Marketing Expense | 123.4M | 136.7M | 137.4M | 244.8M | 307.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 167.7M | 186.1M | 198.5M | 309.9M | 375.3M |
| Cost and Expenses | 347.5M | 339.8M | 349.2M | 495.4M | 603.8M |
| Operating Income (EBIT) | 33.6M | 39.9M | 25.3M | 40.5M | 53.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 31.7M | 38.0M | 25.1M | 39.4M | 51.1M |
| Income Tax Expense | 4.2M | 7.5M | 4.5M | 5.1M | 7.2M |
| Bottom Line | |||||
| Net Income | 27.5M | 30.5M | 20.6M | 34.3M | 43.9M |
| Earnings from Cont. Ops | 27.5M | 30.5M | 20.6M | 34.3M | 43.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 27.5M | 30.5M | 20.6M | 34.3M | 43.9M |
| Per Share | |||||
| Basic EPS | CN¥0.05 | CN¥0.06 | CN¥0.04 | CN¥0.07 | CN¥0.09 |
| Diluted EPS | CN¥0.05 | CN¥0.06 | CN¥0.04 | CN¥0.07 | CN¥0.09 |
| Revenue Per Share | CN¥0.61 | CN¥0.76 | CN¥0.74 | CN¥1.05 | CN¥1.30 |
| Shares | |||||
| Basic Shares Outstanding | 632.3M | 507.1M | 507.7M | 507.7M | 507.3M |
| Diluted Shares Outstanding | 632.3M | 507.1M | 507.7M | 507.7M | 507.3M |
| Profitability Metrics | |||||
| EBITDA | — | 63.2M | 45.0M | 64.7M | 79.8M |
| D&A | — | 23.3M | 19.7M | 24.2M | 25.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026